JP2010535214A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010535214A5 JP2010535214A5 JP2010519939A JP2010519939A JP2010535214A5 JP 2010535214 A5 JP2010535214 A5 JP 2010535214A5 JP 2010519939 A JP2010519939 A JP 2010519939A JP 2010519939 A JP2010519939 A JP 2010519939A JP 2010535214 A5 JP2010535214 A5 JP 2010535214A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- difluoro
- benzamide
- thiophen
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 10
- 238000006243 chemical reaction Methods 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 238000011282 treatment Methods 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 4
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 4
- 208000010668 atopic eczema Diseases 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 206010002198 Anaphylactic reaction Diseases 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 108010002350 Interleukin-2 Proteins 0.000 claims 2
- 102000004310 Ion Channels Human genes 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 206010047115 Vasculitis Diseases 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- 230000000172 allergic effect Effects 0.000 claims 2
- 208000003455 anaphylaxis Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 210000002865 immune cell Anatomy 0.000 claims 2
- 210000000987 immune system Anatomy 0.000 claims 2
- 208000026278 immune system disease Diseases 0.000 claims 2
- 230000004968 inflammatory condition Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 238000011321 prophylaxis Methods 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 201000009890 sinusitis Diseases 0.000 claims 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- QVBMLLKABAKUEC-UHFFFAOYSA-N 2,6-difluoro-n-[4-(3-methyl-5-pyridin-3-ylthiophen-2-yl)phenyl]benzamide Chemical compound CC=1C=C(C=2C=NC=CC=2)SC=1C(C=C1)=CC=C1NC(=O)C1=C(F)C=CC=C1F QVBMLLKABAKUEC-UHFFFAOYSA-N 0.000 claims 1
- VURDERBCIUUPJU-UHFFFAOYSA-N 2,6-difluoro-n-[4-[2-methyl-5-(1,3,4-oxadiazol-2-yl)thiophen-3-yl]phenyl]benzamide Chemical compound CC=1SC(C=2OC=NN=2)=CC=1C(C=C1)=CC=C1NC(=O)C1=C(F)C=CC=C1F VURDERBCIUUPJU-UHFFFAOYSA-N 0.000 claims 1
- NBKIOHYCZNRTAF-UHFFFAOYSA-N 2,6-difluoro-n-[4-[2-methyl-5-(4-methylpyridin-3-yl)thiophen-3-yl]phenyl]benzamide Chemical compound CC=1SC(C=2C(=CC=NC=2)C)=CC=1C(C=C1)=CC=C1NC(=O)C1=C(F)C=CC=C1F NBKIOHYCZNRTAF-UHFFFAOYSA-N 0.000 claims 1
- BJUPEDBRBVKQIK-UHFFFAOYSA-N 2,6-difluoro-n-[4-[5-(1h-imidazol-5-yl)-2-methylthiophen-3-yl]phenyl]benzamide Chemical compound CC=1SC(C=2NC=NC=2)=CC=1C(C=C1)=CC=C1NC(=O)C1=C(F)C=CC=C1F BJUPEDBRBVKQIK-UHFFFAOYSA-N 0.000 claims 1
- UVGPFCQXXQFXLB-UHFFFAOYSA-N 2,6-difluoro-n-[4-[5-(4-methoxypyridin-3-yl)-2-methylthiophen-3-yl]phenyl]benzamide Chemical compound COC1=CC=NC=C1C1=CC(C=2C=CC(NC(=O)C=3C(=CC=CC=3F)F)=CC=2)=C(C)S1 UVGPFCQXXQFXLB-UHFFFAOYSA-N 0.000 claims 1
- SLWNYRLLIBVJIG-UHFFFAOYSA-N 2,6-difluoro-n-[5-[2-methyl-5-(3-methylimidazol-4-yl)thiophen-3-yl]pyrazin-2-yl]benzamide Chemical compound CC=1SC(C=2N(C=NC=2)C)=CC=1C(N=C1)=CN=C1NC(=O)C1=C(F)C=CC=C1F SLWNYRLLIBVJIG-UHFFFAOYSA-N 0.000 claims 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000030767 Autoimmune encephalitis Diseases 0.000 claims 1
- 208000015338 Autoimmune hepatitis type 1 Diseases 0.000 claims 1
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 claims 1
- 208000037157 Azotemia Diseases 0.000 claims 1
- 208000023514 Barrett esophagus Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- 208000006386 Bone Resorption Diseases 0.000 claims 1
- 208000020084 Bone disease Diseases 0.000 claims 1
- IFPYPNKQKUNWRX-UHFFFAOYSA-O CC([S+](C=C1)C2=CN=CN2)=C1C(N=C1)=CN=C1C(C=CC(F)=C1C(N)=O)=C1F Chemical compound CC([S+](C=C1)C2=CN=CN2)=C1C(N=C1)=CN=C1C(C=CC(F)=C1C(N)=O)=C1F IFPYPNKQKUNWRX-UHFFFAOYSA-O 0.000 claims 1
- 208000031229 Cardiomyopathies Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- 206010010996 Corneal degeneration Diseases 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 208000016192 Demyelinating disease Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010014612 Encephalitis viral Diseases 0.000 claims 1
- 208000010334 End Stage Liver Disease Diseases 0.000 claims 1
- 208000004262 Food Hypersensitivity Diseases 0.000 claims 1
- 206010016946 Food allergy Diseases 0.000 claims 1
- 208000007465 Giant cell arteritis Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000006877 Insect Bites and Stings Diseases 0.000 claims 1
- 102100037850 Interferon gamma Human genes 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 claims 1
- 102000003816 Interleukin-13 Human genes 0.000 claims 1
- 108090000176 Interleukin-13 Proteins 0.000 claims 1
- 102000000588 Interleukin-2 Human genes 0.000 claims 1
- 108090000978 Interleukin-4 Proteins 0.000 claims 1
- 102000004388 Interleukin-4 Human genes 0.000 claims 1
- 108010002616 Interleukin-5 Proteins 0.000 claims 1
- 102000000743 Interleukin-5 Human genes 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 208000003926 Myelitis Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010033078 Otitis media Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 201000011152 Pemphigus Diseases 0.000 claims 1
- 208000031845 Pernicious anaemia Diseases 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 206010058141 Skin graft rejection Diseases 0.000 claims 1
- 201000002661 Spondylitis Diseases 0.000 claims 1
- 206010042742 Sympathetic ophthalmia Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 206010047642 Vitiligo Diseases 0.000 claims 1
- 230000001919 adrenal effect Effects 0.000 claims 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 229940035676 analgesics Drugs 0.000 claims 1
- 239000000730 antalgic agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- 229940125715 antihistaminic agent Drugs 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
- 201000004982 autoimmune uveitis Diseases 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 230000024279 bone resorption Effects 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000011444 chronic liver failure Diseases 0.000 claims 1
- 208000024035 chronic otitis media Diseases 0.000 claims 1
- 230000016396 cytokine production Effects 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010014801 endophthalmitis Diseases 0.000 claims 1
- 235000020932 food allergy Nutrition 0.000 claims 1
- 208000007565 gingivitis Diseases 0.000 claims 1
- 208000009326 ileitis Diseases 0.000 claims 1
- 229940125721 immunosuppressive agent Drugs 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 201000001371 inclusion conjunctivitis Diseases 0.000 claims 1
- 208000013256 infectious meningitis Diseases 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 239000004816 latex Substances 0.000 claims 1
- 229920000126 latex Polymers 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- BMJSTMBWWGUHHZ-UHFFFAOYSA-N n-[4-[5-(3-ethylimidazol-4-yl)-2-methylthiophen-3-yl]phenyl]-2,6-difluorobenzamide Chemical compound CCN1C=NC=C1C1=CC(C=2C=CC(NC(=O)C=3C(=CC=CC=3F)F)=CC=2)=C(C)S1 BMJSTMBWWGUHHZ-UHFFFAOYSA-N 0.000 claims 1
- BQQBYVPSZVQMPN-UHFFFAOYSA-N n-[4-[5-(4-chloropyridin-3-yl)-2-methylthiophen-3-yl]phenyl]-2,6-difluorobenzamide Chemical compound CC=1SC(C=2C(=CC=NC=2)Cl)=CC=1C(C=C1)=CC=C1NC(=O)C1=C(F)C=CC=C1F BQQBYVPSZVQMPN-UHFFFAOYSA-N 0.000 claims 1
- VRMUJAXIEMIPOU-UHFFFAOYSA-N n-[4-[5-(5-chloro-2-methoxypyridin-3-yl)-2-methylthiophen-3-yl]phenyl]-2,6-difluorobenzamide Chemical compound COC1=NC=C(Cl)C=C1C1=CC(C=2C=CC(NC(=O)C=3C(=CC=CC=3F)F)=CC=2)=C(C)S1 VRMUJAXIEMIPOU-UHFFFAOYSA-N 0.000 claims 1
- 210000000653 nervous system Anatomy 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 201000001976 pemphigus vulgaris Diseases 0.000 claims 1
- 201000001245 periodontitis Diseases 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 201000011461 pre-eclampsia Diseases 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 210000000278 spinal cord Anatomy 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 206010043207 temporal arteritis Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 206010044325 trachoma Diseases 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 201000008827 tuberculosis Diseases 0.000 claims 1
- 208000009852 uremia Diseases 0.000 claims 1
- 201000002498 viral encephalitis Diseases 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Divinylene sulfide Natural products C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 238000006069 Suzuki reaction reaction Methods 0.000 description 3
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- -1 aminophenyl Chemical group 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 125000001246 bromo group Chemical class Br* 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229930192474 thiophene Natural products 0.000 description 2
- LNYYVHNIHCOWCB-UHFFFAOYSA-N 2-methylpyridine-4-carbonyl chloride Chemical compound CC1=CC(C(Cl)=O)=CC=N1 LNYYVHNIHCOWCB-UHFFFAOYSA-N 0.000 description 1
- HETSCJCZMZWQMJ-UHFFFAOYSA-N 3-methyl-n-[4-(3-methyl-5-pyrimidin-5-ylthiophen-2-yl)phenyl]pyridine-4-carboxamide Chemical compound CC=1C=C(C=2C=NC=NC=2)SC=1C(C=C1)=CC=C1NC(=O)C1=CC=NC=C1C HETSCJCZMZWQMJ-UHFFFAOYSA-N 0.000 description 1
- PHKSPGLTXLMXIN-UHFFFAOYSA-N 5-(4-methylthiophen-2-yl)pyrimidine Chemical compound CC1=CSC(C=2C=NC=NC=2)=C1 PHKSPGLTXLMXIN-UHFFFAOYSA-N 0.000 description 1
- YYTDZXLXMXLZKN-UHFFFAOYSA-N 5-(5-bromo-4-methylthiophen-2-yl)pyrimidine Chemical compound S1C(Br)=C(C)C=C1C1=CN=CN=C1 YYTDZXLXMXLZKN-UHFFFAOYSA-N 0.000 description 1
- GYCPLYCTMDTEPU-UHFFFAOYSA-N 5-bromopyrimidine Chemical compound BrC1=CN=CN=C1 GYCPLYCTMDTEPU-UHFFFAOYSA-N 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical class OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- NTNLWSYOFAXBGI-UHFFFAOYSA-N methyl 4-[4-[(2,6-difluorobenzoyl)amino]phenyl]-5-methylthiophene-2-carboxylate Chemical compound S1C(C(=O)OC)=CC(C=2C=CC(NC(=O)C=3C(=CC=CC=3F)F)=CC=2)=C1C NTNLWSYOFAXBGI-UHFFFAOYSA-N 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US96282407P | 2007-08-01 | 2007-08-01 | |
| US60/962,824 | 2007-08-01 | ||
| PCT/US2008/009305 WO2009017818A1 (en) | 2007-08-01 | 2008-07-31 | Heterocycle-aryl compounds for inflammation and immune-related uses |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010535214A JP2010535214A (ja) | 2010-11-18 |
| JP2010535214A5 true JP2010535214A5 (enExample) | 2012-10-04 |
| JP5511664B2 JP5511664B2 (ja) | 2014-06-04 |
Family
ID=40304688
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010519939A Expired - Fee Related JP5511664B2 (ja) | 2007-08-01 | 2008-07-31 | 炎症および免疫関連用途のための複素環−アリール化合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US8435996B2 (enExample) |
| EP (1) | EP2184994B1 (enExample) |
| JP (1) | JP5511664B2 (enExample) |
| CA (1) | CA2695143A1 (enExample) |
| ES (1) | ES2440267T3 (enExample) |
| TW (1) | TWI444186B (enExample) |
| WO (1) | WO2009017818A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1846388A4 (en) | 2005-01-25 | 2011-12-07 | Synta Pharmaceuticals Corp | THIOPHEN COMPOUNDS FOR IGNITIONS AND THE IMMUNE SYSTEM APPLICATIONS |
| TW200806641A (en) | 2006-01-25 | 2008-02-01 | Synta Pharmaceuticals Corp | Substituted aromatic compounds for inflammation and immune-related uses |
| US7816535B2 (en) | 2006-01-25 | 2010-10-19 | Synta Pharmaceuticals Corp. | Vinyl-phenyl derivatives for inflammation and immune-related uses |
| TW200806290A (en) | 2006-01-25 | 2008-02-01 | Synta Pharmaceuticals Corp | Substituted biaryl compounds for inflammation and immune-related uses |
| AU2007227210A1 (en) | 2006-03-20 | 2007-09-27 | Synta Pharmaceuticals Corp. | Benzoimidazolyl-parazine compounds for inflammation and immune-related uses |
| US8779154B2 (en) | 2006-09-26 | 2014-07-15 | Qinglin Che | Fused ring compounds for inflammation and immune-related uses |
| AU2009300317A1 (en) | 2008-10-01 | 2010-04-08 | Synta Pharmaceuticals Corp. | Compounds for inflammation and immune-related uses |
| US8993612B2 (en) | 2009-10-08 | 2015-03-31 | Rhizen Pharmaceuticals Sa | Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer |
| US8377970B2 (en) | 2009-10-08 | 2013-02-19 | Rhizen Pharmaceuticals Sa | Modulators of calcium release-activated calcium channel |
| US20120231006A1 (en) | 2009-11-20 | 2012-09-13 | Amgen Inc. | Anti-orai1 antigen binding proteins and uses thereof |
| EP2563759B1 (en) | 2010-04-27 | 2022-04-06 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| JP6112486B2 (ja) | 2010-04-27 | 2017-04-12 | カルシメディカ，インク． | 細胞内カルシウムを調節する化合物 |
| US10703722B2 (en) | 2010-04-27 | 2020-07-07 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| EP2609095A4 (en) | 2010-08-27 | 2014-06-18 | Calcimedica Inc | COMPOUNDS MODULATING INTRACELLULAR CALCIUM |
| US20120316182A1 (en) | 2011-06-10 | 2012-12-13 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| WO2013059677A1 (en) | 2011-10-19 | 2013-04-25 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| US9512116B2 (en) | 2012-10-12 | 2016-12-06 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| EP2738172A1 (en) | 2012-11-28 | 2014-06-04 | Almirall, S.A. | New bicyclic compounds as crac channel modulators |
| EP2848615A1 (en) | 2013-07-03 | 2015-03-18 | Almirall, S.A. | New pyrazole derivatives as CRAC channel modulators |
| EP3778595B1 (en) | 2015-02-27 | 2021-08-25 | Calcimedica, Inc. | Pancreatitis treatment |
| CA2995094A1 (en) | 2015-08-07 | 2017-02-16 | Calcimedica, Inc. | Use of crac channel inhibitors for the treatment of stroke and traumatic brain injury |
| WO2020053834A1 (en) | 2018-09-14 | 2020-03-19 | Rhizen Pharmaceuticals Sa | Compositions comprising a crac inhibitor and a corticosteroid and methods of use thereof |
| TWI885039B (zh) | 2020-01-13 | 2025-06-01 | 美商邊際分析公司 | 經取代吡唑并嘧啶及其用途 |
| JP2023528537A (ja) | 2020-03-20 | 2023-07-04 | カルシメディカ，インク． | 急性肺傷害及び急性呼吸窮迫症候群を処置するための方法及び組成物 |
| GB202006076D0 (en) * | 2020-04-24 | 2020-06-10 | Univ Greenwich | Interleukin inhibitors |
| CA3198798A1 (en) | 2020-11-13 | 2022-05-19 | Kenneth Stauderman | Improved synthesis of crac channel inhibitors |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| US6274171B1 (en) | 1996-03-25 | 2001-08-14 | American Home Products Corporation | Extended release formulation of venlafaxine hydrochloride |
| PL1848435T3 (pl) * | 2005-01-25 | 2016-08-31 | Synta Pharmaceuticals Corp | Związki przeciwko zapaleniom i zastosowania związane z odpornością |
| US7930013B2 (en) | 2005-06-29 | 2011-04-19 | Compumedics Limited | Sensor assembly with conductive bridge |
| WO2007087429A2 (en) * | 2006-01-25 | 2007-08-02 | Synta Pharmaceuticals Corp. | Phenyl and pyridyl compounds for inflammation and immune-related uses |
-
2008
- 2008-07-31 CA CA2695143A patent/CA2695143A1/en not_active Abandoned
- 2008-07-31 WO PCT/US2008/009305 patent/WO2009017818A1/en not_active Ceased
- 2008-07-31 TW TW097128954A patent/TWI444186B/zh not_active IP Right Cessation
- 2008-07-31 ES ES08794963.2T patent/ES2440267T3/es active Active
- 2008-07-31 JP JP2010519939A patent/JP5511664B2/ja not_active Expired - Fee Related
- 2008-07-31 US US12/452,979 patent/US8435996B2/en not_active Expired - Fee Related
- 2008-07-31 EP EP08794963.2A patent/EP2184994B1/en not_active Not-in-force
-
2013
- 2013-04-03 US US13/855,803 patent/US20130236481A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010535214A5 (enExample) | ||
| JP2010535218A5 (enExample) | ||
| CA2669695A1 (en) | Tetrahydropyridinyl compounds for inflammation and immune-related uses | |
| JP2010535215A5 (enExample) | ||
| JP2010509342A5 (enExample) | ||
| JP2012504605A5 (enExample) | ||
| US10399967B2 (en) | Compounds for inflammation and immune-related uses | |
| JP4621198B2 (ja) | トリ（シクロ）置換アミドグルコキナーゼ活性化化合物 | |
| JP4575918B2 (ja) | ４−アリル−ニコチンアミド誘導体の製造方法 | |
| MX2010013058A (es) | Derivado de benceno o tiofeno y su uso como inhibidor de proteina 1 de adhesion vascular. | |
| JP2008513508A5 (enExample) | ||
| CA2640090A1 (en) | Substituted aromatic compounds for inflammation and immune-related uses | |
| KR20070110303A (ko) | 염증 및 면역 관련 용도를 위한 화합물 | |
| JP4669839B2 (ja) | ジフェニルピリジン誘導体、その製造法および治療用途 | |
| WO2005009539A2 (en) | Compounds for inflammation and immune-related uses | |
| TW200800188A (en) | Pyridylphenyl compounds for inflammation and immune-related uses | |
| AU2007227210A1 (en) | Benzoimidazolyl-parazine compounds for inflammation and immune-related uses | |
| KR20150079963A (ko) | 키나제 조절제로서 유용한 헤테로아릴 치환된 피리딜 화합물 | |
| JP2009524677A (ja) | 炎症および免疫関連使用用のチアゾールおよびチアジアゾール化合物 | |
| JP2008526866A (ja) | 炎症及び免疫に関連する用途に用いる化合物 | |
| WO2013062065A1 (ja) | アミノアルキル置換n-チエニルベンズアミド誘導体 | |
| HK1220195A1 (zh) | 恶唑及异恶唑钙释放激活的钙调节剂 | |
| JP2012524107A5 (enExample) | ||
| JP2019520317A (ja) | ベンゾイルグリシン誘導体およびその作製および使用の方法 | |
| JP2016508152A (ja) | Ｃｒａｃチャネル阻害薬としての、ピラゾリルをベースとするカルボキサミド類ｉ |